This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reist, C. J. Articles by Zalutsky, M. R. Search for Related Content PubMed PubMed Citation Articles by Reist, C. J. Articles by Zalutsky, M. R.

Radioiodination of Internalizing Monoclonal Antibodies Using N-Succinimidyl 5-Iodo-3-Pyridinecarboxylate¹

Departments of Pathology [C. J. R., D. D. B., M. R. Z.] and Radiology [P. K. G., K. L. A., M. R. Z.], Duke University Medical Center, Durham, North Carolina 27710

Monoclonal antibodies (mAbs) that internalize following binding to cell-surface receptors require radiolabeling approaches that minimize loss of radioactivity from the cell after intracellular processing. One class of internalizing mAbs of great interest for imaging and radioimmunotherapy are those specific for EGFRvIII, a truncated form of the epidermal growth factor receptor found on gliomas, non-small cell lung carcinomas, breast carcinomas, and ovarian carcinomas. Because lysosomes are known to retain positively charged compounds, N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC) might be ideal for radioiodination of these mAbs because of the positive charge on its pyridine ring. To investigate this hypothesis, the anti-EGFRvIII mAb L8A4 was labeled using SIPC, and internalization assays were performed using the EGFRvIII-positive cell lines HC2 20 d2 and NR6M. Compared with L8A4 labeled using Iodogen or N-succinimidyl 3-iodobenzoate, SIPC increased intracellular retention of activity by up to 65%. Reverse-phase high-performance liquid chromatography analyses indicated that a significantly higher fraction of the low molecular weight catabolites from mAbs labeled via SIPC were retained within cells (SIPC, 28.1%; Iodogen, 7.6% at 1 h). With SIPC, the primary labeled species in cell lysates was the 5-iodonicotinic acid (INA)-lysine conjugate, whereas in the supernatant, both INA-lysine and INA were seen. A 3–4-fold higher percentage of these catabolites were charged at lysosomal pH in comparison with those from mAb labeled using N-succinimidyl 3-iodobenzoate, in concert with the differences in cellular retention observed between these two labeling methods. In mice bearing HC2 20 d2 xenografts, a significant improvement in tumor retention of radioiodine and tumor:normal tissue ratios was seen when L8A4 was labeled using SIPC instead of the Iodogen method. These results suggest that SIPC is a promising reagent for the radioiodination of anti-EGFRvIII L8A4 and, possibly, other internalizing mAbs.

¹ Supported in part by NIH Grants CA42324, NS20023, and CA11898 and Grant DE-FG02-96ER62148 from the United States Department of Energy.

² Current address: Yale University/VA PET Center, 950 Campbell Avenue, West Haven, CT 06516.

³ To whom requests for reprints should be addressed, at Duke University Medical Center, Department of Radiology, Box 3808, Durham, NC 27710.

Received 3/25/96. Accepted 9/ 3/96.

This article has been cited by other articles:

				R. Stein, S. V. Govindan, M. Hayes, G. L. Griffiths, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody Clin. Cancer Res., April 1, 2005; 11(7): 2727 - 2734. [Abstract] [Full Text] [PDF]

				S. V. Govindan, G. L. Griffiths, R. Stein, P. Andrews, R. M. Sharkey, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Clinical-Scale Radiolabeling of a Humanized Anticarcinoembryonic Antigen Monoclonal Antibody, hMN-14, with Residualizing 131I for Use in Radioimmunotherapy J. Nucl. Med., January 1, 2005; 46(1): 153 - 159. [Abstract] [Full Text] [PDF]

				Z. Cheng, J. Chen, T. P. Quinn, and S. S. Jurisson Radioiodination of Rhenium Cyclized {alpha}-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma Cancer Res., February 15, 2004; 64(4): 1411 - 1418. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, M. J. Mattes, S. Chen, L. Reed, G. Newsome, B. J. McBride, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg Improved Iodine Radiolabels for Monoclonal Antibody Therapy Cancer Res., January 1, 2003; 63(1): 111 - 118. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, S. Chen, L. Reed, H. Richel, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I J. Nucl. Med., June 1, 2001; 42(6): 967 - 974. [Abstract] [Full Text] [PDF]

				C. F. Foulon, C. J. Reist, D. D. Bigner, and M. R. Zalutsky Radioiodination via D-Amino Acid Peptide Enhances Cellular Retention and Tumor Xenograft Targeting of an Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody Cancer Res., August 1, 2000; 60(16): 4453 - 4460. [Abstract] [Full Text]

				C.-T. Kuan, C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts Clin. Cancer Res., June 1, 1999; 5(6): 1539 - 1549. [Abstract] [Full Text] [PDF]

				M. B. Vrouenraets, G. W. M. Visser, F. A. Stewart, M. Stigter, H. Oppelaar, P. E. Postmus, G. B. Snow, and G. A. M. S. van Dongen Development of meta-Tetrahydroxyphenylchlorin-Monoclonal Antibody Conjugates for Photoimmunotherapy Cancer Res., April 1, 1999; 59(7): 1505 - 1513. [Abstract] [Full Text] [PDF]